Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

recurrent Pancreatic Neuroendocrine Tumors (Islet Cell Tumors)

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

Treatment of Recurrent and Progressive Pancreatic Neuroendocrine Tumors

Broader topic: Pancreatic Neuroendocrine Tumors (Islet Cell Tumors)

Source population
Not part of this definition
Disease extent
recurrent
Treatment line
Not part of this definition
Stage
Not part of this definition
Resectability
Not part of this definition
Biomarkers, prior therapy and derivation
molecular
    prior therapy
    1. class
      prior therapy
      status
      stated
    derivation status
    source-attested
    derivation note
    Scoped from an NCI treatment-summary heading. NCI PDQ is an evidence summary, not a practice guideline, and only the dimensions the heading states are part of this definition.
    source wording
    Treatment of Recurrent and Progressive Pancreatic Neuroendocrine Tumors

    Study evidence for this setting

    1 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

    NCT01010126 · Registry condition search · Scope: unclear

    Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

    6 outcome links · 6 safety-group records · 0 quality-of-life measures

    →
    Source relationships and population-mapping limitations
    bindings
      mappings

        Download this complete draft source relationship record →

        Preserved source evidence · Not medical advice